Literature DB >> 18366264

[Assessing the use of proton pump inhibitors in an internal medicine department].

E Martín-Echevarría1, A Pereira Juliá, M Torralba, G Arriola Pereda, P Martín Dávila, J Mateos, M Rodríguez Zapata.   

Abstract

INTRODUCTION: proton pump inhibitors (PPIs) block the H+/K+ ATPase enzyme in gastric wall cells, leading to an inhibition of both baseline and stimulated acid secretion. Appropriate indications include: Gastroesophageal reflux, acute upper gastrointestinal bleeding, erosive gastritis or esophagitis, dyspepsia, NSAID-related gastropathy, and stress ulcer prophylaxis in high risk patients. The aims of this study were to review the current indications of PPIs, and to evaluate their use in Guadalajara s University Hospital.
MATERIAL AND METHODS: a transversal, analytic, randomized study was carried out during 2003 in our internal medicine department. A total of 208 medical records for 832 patients receiving PPIs were reviewed (25%). Mean age was 67 years (range: 16-92), 46.2% were females, and most frequent conditions were HBP, COPD, and DM.
RESULTS: 34.6% of patients took PPIs before admission, their use being inappropriate in 68.1% of them. Among hospitalized patients 73.03% used PPIs inappropriately, and most of them had no such indication at discharge.
CONCLUSIONS: results are in accordance with the literature, with a high frequency of incorrect PPI use; a more accurate use of PPIs is to be recommended to avoid side effects and drug interactions, and to provide a more efficient medical care.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18366264     DOI: 10.4321/s1130-01082008000200003

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  3 in total

1.  Use of acid suppressive therapy in hospitalized non-critically ill patients.

Authors:  Marwan Sheikh-Taha; Sarah Alaeddine; Julie Nassif
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-12-06

2.  Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.

Authors:  Hee Jeong Lee; Haekyung Lee; Song Hee Oh; Joonbyung Park; Suyeon Park; Jin Seok Jeon; HyunJin Noh; Dong Cheol Han; Soon Hyo Kwon
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

3.  Prescribing patterns and economic costs of proton pump inhibitors in Colombia.

Authors:  Jorge Machado-Alba; Alejandra Fernández; Juan Daniel Castrillón; Carlos Felipe Campo; Luis Felipe Echeverri; Andrés Gaviria; Manuel José Londoño; Sergio Andrés Ochoa; Joaquín Octavio Ruíz
Journal:  Colomb Med (Cali)       Date:  2013-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.